tiprankstipranks
Q32 Bio downgraded to Market Perform from Outperform at Leerink
The Fly

Q32 Bio downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $9, down from $68, following disappointing results for lead asset bempikibart from the Phase 2a SIGNAL-AD and SIGNAL-AA studies. The firm has removed value for atopic dermatitis from its model and adjusted its probability of success and market penetration assumptions for alopecia areata. The firm is moving to the sidelines, pending further analyses, signal refinement, and greater clarity on the path forward for bempi in AA and/or emergence of ADX-097 in renal indications.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App